Comparing the current results to its competitors, Viking Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 16.3 %, recorded in the same quarter.
Viking Therapeutics Inc , slower than the average decrease reported by the company's competitors of -2.55 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -2.55 %
Viking Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the biopharmaceutical industry, which is characterized by rapid technological advancements and a focus on proprietary products. It faces competition from commercial biopharmaceutical enterprises, academic institutions, government agencies, and private and public research institutions. Competitors often possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. Smaller or early-stage companies may also present competition, particularly through collaborations with larger firms. Competitors may develop therapies that are more effective, better tolerated, or less costly, potentially rendering the company's drug candidates obsolete or noncompetitive. Additionally, competitors may obtain regulatory approvals before the company.
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Processa Pharmaceuticals Inc is a biopharmaceutical company that operates by developing and commercializing innovative drug candidates for various medical conditions. They focus on advancing treatments through clinical trials, obtaining regulatory approvals, and partnering with other healthcare organizations for distribution and marketing.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Viking Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Viking Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
